EIM
NGM

Essex Investment Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Essex Investment Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-44,805
Closed -$621K – 516
2019
Q3 		$621K Buy
+44,805
New +$672K 0.09% 268

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Essex Investment Management's NGM Position: Q4 2019 in Review

Essex Investment Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2019, closing a stake of 44,805 shares — an estimated $621K sold.

Essex Investment Management first reported a position in NGM in Q3 2019 and held it in 1 quarter. The position peaked at $621K in Q3 2019. 59 funds tracked by Wall St. Rank hold NGM as of Q4 2019.

  • Essex Investment Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Essex Investment Management sold 44,805 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $621K.
  • Essex Investment Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Essex Investment Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $621K in Q3 2019.
  • 59 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Essex Investment Management's 13F filing for Q4 2019, filed 10 Feb 2020.